



Events Jobs Subscribe Contact Us 🎔 f in

Volume 7.31: August 14, 2023

Publications of the Week

ASCL1 Is Activated Downstream of the ROR2/CREB Signaling Pathway to Support Lineage Plasticity in Prostate Cancer

First Author: Nakisa Tabrizian | Senior Author: Amina Zoubeidi *(pictured)* Cell Reports | Vancouver Prostate Centre and UBC



Lineage plasticity is a form of therapy-induced drug resistance. In prostate cancer, androgen receptor (AR) pathway inhibitors potentially lead to the accretion of tumor relapse with loss of AR signaling and a shift from a luminal state to an alternate program. Here, a survey of receptor tyrosine kinases (RTKs) identifies ROR2 as the top upregulated RTK following AR pathway inhibition, which feeds into lineage plasticity by promoting stem-cell-like and neuronal networks. Abstract

DNA-PK Inhibition Extends the Therapeutic Effects of Top2 Poisoning to Non-Proliferating Cells, Increasing Activity at a Cost

First Author: Taixiang Wang | Senior Author: Andrew Minchinton *(pictured)* Scientific Reports | BC Cancer Research Institute



Type II topoisomerase (Top2) poisoning therapy is used to treat a broad range of cancers via induction of double strand breaks in cells undergoing replication and transcription. To elucidate the cellular mechanisms leading to synergistic activity of dual DNA-dependent protein kinase (DNA-PK)/Top2 inhibition the authors looked at their effects in cycling versus non-cycling cells, in 3D spheroids and in xenograft models. Abstract

View All Publications

Awards

Faculty of Medicine Members Among 2023 Order of BC Recipients

UBC Faculty of Medicine



UBC Faculty of Medicine community members Drs. Penny Ballem, Jane Buxton, and Pieter Cullis *(pictured)* have been appointed to the Order of British Columbia, the province's highest form of recognition. They are among fourteen exceptional people receiving the Order in 2023. The honour is bestowed annually in recognition of outstanding provincial, national or international impact. **Read More**

Celebrating Research Excellence: Nine Scholars Recognized as Distinguished SFU Professors

SFU



Nine researchers have been named 2023 Distinguished SFU Professors in recognition of their exceptional performance and distinguished accomplishments relative to their rank and years of service. This includes Dr. David Vocadlo *(pictured)*, whose interdisciplinary research focuses on developing and using new chemical tools to improve our understanding of how carbohydrates influence cell function. **Read More**

Local News

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

Algernon Pharmaceuticals



Algernon Pharmaceuticals has announced that its subsidiary Algernon NeuroScience has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study. Algernon NeuroScience is the world's first company to investigate DMT for the treatment of stroke and its ability to promote neuroplasticity in the healing of brain injuries. **Read More**

NervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB Approval

NervGen Pharma



NervGen Pharma, a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has received Institutional Review Board (IRB) approval for its landmark Phase 1b/2a proof-ofconcept clinical trial protocol of its proprietary lead compound, NVG-291, in individuals with spinal cord injury. NervGen is now actively recruiting potential subjects. **Read More**

Combining Genomic Insights and Traditional Indigenous Knowledge for the Conservation of Pacific Salmon

Genome BC



A new research project is investigating whether the solution to the sinking salmon numbers may come from combining modern genomic science with traditional fisheries conservation techniques practiced by the Tsleil-Waututh people for over 2,000 years. The project is funded by Genome BC with a research team drawn from the Tsleil-Waututh Nation and SFU's Department of Archaeology and UBC's Institute for the Oceans and Fisheries. **Read More**

Hepatitis C Cure Does Not Remove All Risks, CTN Investigators Find

CIHR Canadian HIV Trials Network (CTN)



CTN Investigators Drs. Naveed Janjua and Sofia Bartlett *(pictured)*, along with a team of researchers from Canada and the UK, have made a significant observation pertaining to individuals who have been successfully cured of hepatitis C (HCV) infection. The study, which is the largest and most representative of its kind to date, reveals that despite there being a cure for HCV, treated individuals still face a significantly higher risk of death compared to the general population. **Read More**


View All Articles 🕤 | Submit an Article 😜

Upcoming Events in Vancouver

September 12Back to Science Slam7:30 PMFox Cabaret

September 14 5:00 PM

25th Annual Life Sciences BC Awards Presented by Farris Vancouver Convention Centre West



STEMCELL Technologies STEMCELL Science News The Stem Cell Podcast

Products | Services Free Weekly Updates on Your Field Interviews and Updates

on Stem Cell Science

SCIENCE IN THE CITY is an official mark of McMaster University and it is used and registered by STEMCELL Technologies Canada Inc. in Canada with the consent of McMaster University.